|
|
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.
Eris Lifescience Strengths:
• Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders
• Portfolio of high volume and leading brands
• Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists
• Multi-faceted product selection and engagement model leading to growth in prescription
• Strong sales, marketing and distribution capabilities
The Promoters of the Company are:
1. Mr. Amit Indubhushan Bakshi,
2. Mr. Himanshu Jayantbhai Shah,
3. Mr. Inderjeet Singh Negi,
4. Mr. Rajendrakumar Rambhai Patel and
5. Mr. Kaushal Kamlesh Shah.
| Particulars | For the year/period ended (in Rs. Million) | |||||
|---|---|---|---|---|---|---|
| 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | ||
| Total Assets | 3,973.59 | 3,572.85 | 2,705.99 | 1,718.05 | 1,019.67 | |
| Total Revenue | 5,970.21 | 5,455.58 | 5,088.22 | 3,930.64 | 2,739.40 | |
| Profit After Tax | 1,348.58 | 892.59 | 709.12 | 584.40 | 370.63 | |
The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. For the sale of up to 28,875,000 Equity Shares by the Selling Shareholders.
| IPO Opening Date | Jun 16, 2017 |
| IPO Closing Date | Jun 20, 2017 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹1 per equity share |
| IPO Price | ₹600 to ₹603 per equity share |
| Market Lot | 24 Shares |
| Min Order Quantity | 24 Shares |
| Listing At | BSE, NSE |
| Issue Size | 28,875,000 Eq Shares of ₹1 (aggregating up to ₹1,741.16 Cr) |
| Offer for Sale | 28,875,000 Eq Shares of ₹1 (aggregating up to ₹[.] Cr) |
| Employee Discount | ? 60 per share |
The Eris Lifesciences IPO open date is Jun 16, 2017, and the close date is Jun 20, 2017. The issue may list on Jun 29, 2017.
| IPO Open Date | Jun 16, 2017 |
| IPO Close Date | Jun 20, 2017 |
| Basis of Allotment Date | Jun 23, 2017 |
| Initiation of Refunds | Jun 27, 2017 |
| Credit of Shares to Demat Account | Jun 28, 2017 |
| IPO Listing Date | Jun 29, 2017 |
The Eris Lifesciences IPO market lot size is 24 shares. A retail-individual investor can apply for up to 13 lots (312 shares or ₹188,136).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 24 | ₹14,472 |
| Maximum | 13 | 312 | ₹188,136 |
The Eris Lifesciences IPO is subscribed 3.29 times on Jun 20, 2017 17:00. The public issue subscribed 3.51 in the retail category, 4.68 in the QIB category, and 0.45 in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 4.68 |
| NII | 0.45 |
| RII | 3.51 |
| Employee | 0.86 |
| Total | 3.29 |
| Listing Date | Thursday, June 29, 2017 |
| BSE Script Code | 540596 |
| NSE Symbol | ERIS |
| Listing In | B Group of Securities |
| ISIN | INE406M01024 |
| IPO Price | ₹603 per equity share |
| Face Value | ₹1 per equity share |
|
|
|
Eris Lifesciences Limited
7th Floor, Commerce House IV,
Beside Shell Petrol Pump, 100 Feet Road,
Prahladnagar, Ahmedabad 380 015
Phone: +91 79 3045 1111
Email: complianceofficer@erislifesciences.com
Website: http://eris.co.in/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: eris.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
Eris Lifesciences IPO is a main-board IPO of 28,875,000 equity shares of the face value of ₹1 aggregating up to ₹1,741.16 Crores. The issue is priced at ₹600 to ₹603 per equity share. The minimum order quantity is 24 Shares.
The IPO opens on Jun 16, 2017, and closes on Jun 20, 2017.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Eris Lifesciences IPO opens on Jun 16, 2017 and closes on Jun 20, 2017.
Eris Lifesciences IPO lot size is 24 Shares and the minimum order quantity is 24 Shares.
You can apply in Eris Lifesciences IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Eris Lifesciences IPO will be done on Jun 23, 2017, and the allotted shares will be credited to your demat account by Jun 28, 2017. Check the Eris Lifesciences IPO allotment status.
Useful Articles
Rs 0 Eq Delivery Brokerage
Flat ₹10 Per Trade in F&O
Rs 0 Demat AMC
Top Contributor (300+ Posts, 200+ Likes)
IPO Mentor (600+ Posts, 800+ Likes)
IPO Guru (2200+ Posts, 2300+ Likes)
i am lucky that i did not get allotment in shipyard...lets see what happens after listing...